Genomic medicine involves the study of a patient’s DNA and how the information can be used to improve clinical care through better diagnosis and personalised treatment.
New Silkroutes Group Limited (NSG) has signed a memorandum of understanding (MOU) with Huawei International to develop an artificial intelligence (AI) platform that can be used in genomics-driven healthcare.
Under the MOU, NSG and Huawei will explore a collaboration to use AI to establish breakthrough analyses into genomic data and develop predictive models for cancel and genomics.
